Within the framework of the last section of the clinical trials of the argentinian vaccine against covid, “ArVac Cecilia Grierson”, from the National Council for Scientific and Technical Research (Conicet) launched a new call for volunteers to Obtain the scientific data that supports the approval of the drug.
In phase 1, 80 volunteers have already participated in phase 1 and so far in this phase 2 and 3, 260. In this instance the safety and immunogenicity of three ArVac formulations will be evaluated -including a bivalent version against Omicron- in 1,782 volunteers.
“What we most need to complete the development of the vaccine is for people to participate as volunteers,” the leader of the ArVac project and researcher at the ArVac project said at a press conference. ConicetJuliana Cassataro.
Requirements to be a volunteer and how to sign up
The call is for residents of the City of Buenos Aires, La Plata, Mar del Plata, Córdoba capital, Mendoza capital, or Salta capital who are 18 years of age or older, and have between 2 and 3 doses of the coronavirus vaccine. To sign up as a volunteer you must complete a online form.
Unlike phase 1, In this instance, people with comorbidities may participate.unless you have a “high” deficiency of the immune response.
For his part, the Minister of Science, Technology and Innovation, Daniel Filmus highlighted that “It is the first time that Argentina has reached this point regarding a vaccineparticularly after having successfully passed phase 1″, and that “this technology will be used to develop many other vaccines“.
New stage of clinical trials
Unlike the first stage of clinical trials, which began in January and the vaccine was administered to 232 people in two Buenos Aires centers (CEMIC and Clinical Pharma); in this stage it would be applied in 10 centers distributed in four provinces and in the City of Buenos Aires.
“If we manage to get the number of volunteers this month, a month and a half later we can analyze all the results and present it to the National Administration of Drugs, Food and Medical Technology (Anmat). We are preparing for, if we manage to get all the volunteers in June, be able to have the presentation“, concluded S.
For his part, Jorge Cassará, commercial director of the Cassará Laboratory, explained that the vaccine is “protein” and the technology is “Very safe“, since it has “the same technology with which children and newborns have been vaccinated for 30 years against Hepatitis B, and more recently in adolescents.”
